Drifa Belhadi

Paris, 75018, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial.

Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: July 23, 2025

Long-term effectiveness and safety of dupilumab in severe asthma: A 5-year real-world multicenter study.

Long-term effectiveness and safety of dupilumab in severe asthma: A 5-year real-world multicenter study.

Journal: The journal of allergy and clinical immunology. In practice

Published: January 14, 2025

Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials.

Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials.

Journal: The Lancet. Respiratory medicine

Published: October 10, 2024

sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.

sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.

Journal: Scientific reports

Published: August 27, 2024

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.

Journal: The Journal of infection

Published: February 02, 2024

Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.

Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.

Journal: EClinicalMedicine

Published: October 13, 2023

Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.

Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: September 28, 2023

Risk factors for acne scarring in Ecuador.

Risk factors for acne scarring in Ecuador.

Journal: PloS one

Published: April 26, 2023

Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients.

Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients.

Journal: CPT: pharmacometrics & systems pharmacology

Published: February 15, 2023

Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study.

Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study.

Journal: Contemporary clinical trials

Published: February 03, 2023

Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.

Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.

Journal: Pharmacology research & perspectives

Published: November 29, 2022

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.

Journal: The Lancet. Respiratory medicine

Published: November 21, 2022

Showing 1-12 of 33

Last Updated: 09/26/2026